Non Small Cell Lung Cancer Clinical Trials in Memphis, Tennessee

11 studies are recruiting for non small cell lung cancer in Memphis, Tennessee right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02)

   This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Cancer Center, Memphis, Tennessee

   Locations

   366 in total

   Run by

   BioNTech SE

   See if you can join NCT06712316 on ClinicalTrials.gov

2. A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to determine if telisotuzumab vedotin works better than …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Duplicate_Memphis VA Medical Center /ID# 263250, Memphis, Tennessee

   Locations

   317 in total

   Run by

   AbbVie

   See if you can join NCT04928846 on ClinicalTrials.gov

3. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Baptist Memorial Hospital Cancer Center, Memphis, Tennessee

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

4. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

   The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Local Institution - 0199, Memphis, Tennessee

   Locations

   204 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07680790 on ClinicalTrials.gov

5. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

   The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

   Stage

   Phase 2

   Ages

   18 to 95

   Site

   Research Site, Memphis, Tennessee

   Locations

   97 in total

   Run by

   AstraZeneca

   See if you can join NCT05061550 on ClinicalTrials.gov

6. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

   This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Clinical Research Institute, Memphis, Tennessee

   Locations

   38 in total

   Run by

   Genentech, Inc.

   See if you can join NCT04302025 on ClinicalTrials.gov

7. A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

   The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-mutated, advanced or metastatic non squamous non-small cell lung…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Baptist Cancer Center, Memphis, Tennessee

   Locations

   288 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06793215 on ClinicalTrials.gov

8. Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

   This is a non-registrational, cohort study enrolling eligible Black patients diagnosed with histologically or cytologically, advanced/metastatic NSCLC without known EGFR/ALK/ROS1 tumor mutations, and who are ≥ 18 years of age, ECOG performance status 0-2, and may have detectable ctDNA at baseline.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Baptist Clinical Research Institute, Memphis, Tennessee

   Locations

   11 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT06745882 on ClinicalTrials.gov

9. JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer

   To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Tennessee Health Science Center, Memphis, Tennessee

   Locations

   50 in total

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT02468024 on ClinicalTrials.gov

10. GEMINI-NSCLC: NSCLC Biomarker Study

    GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecul…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Baptist Cancer Center, Memphis, Tennessee

    Locations

    58 in total

    Run by

    Tempus AI

    See if you can join NCT05236114 on ClinicalTrials.gov

11. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical…

    Stage

    Not phased

    Ages

    Any age

    Site

    Massive Bio SYNERGY-AI site, Memphis, Tennessee

    Locations

    68 in total

    Run by

    Massive Bio, Inc.

    See if you can join NCT03452774 on ClinicalTrials.gov